PHARMACEUTICAL SOLUTIONS

As the pharmaceutical industry gradually moves towards innovative therapies with customised and patient-specific treatments, manufacturers now are  that specialize in  smaller batch sizes of more complex and potent compounds while also ensuring  top quality  standards. Significant investment in research with  a clear  shift towards specialty drug products, especially oncology, has been  a very  growing area of interest for global pharmaceutical players in recent years. As per reports, approximately  a quarter   of latest  chemical entities (NCEs) under development  fall into  the category of highly potent active pharmaceutical ingredients (HPAPI). Oncology,  a serious  driver  within the  growth of HPAPI, shows tremendous growth potential.  the worldwide  oncology market was valued at USD 16 billion in 2018 and  is predicted  to grow at a CAGR of 8.7% between 2019 and 2025. Challenges of containment An API  is taken into account  highly potent if it meets one or more of several

The  life science  and healthcare systems are evolving daily,  because of  the staggering progress in technology and research. One breakthrough  of those  innovative efforts  is that the  inception of ‘’personalised medicine’’, also called the ‘’precision medicine’’ intervention.  it's  a radical approach to refine  the normal  diagnostic and treatment methods  so as  to supply  precise,  simpler  treatment to the patients with minimum risk  and price  . Although initially perceived as improbable, personalised medicine is becoming more feasible with our improved understanding of  genetic science   and therefore the  advances in related technology. The motivation The origin of the personalised medicine era  are often  traced back to the unfolding of the human genome sequence in 2003. Access to  the entire  human genome sequence  and therefore the  advances in genomics, proteomics, bioinformatics, and data-intensive biomedical assays have enhanced our understanding of inter-indiv